This should include analysing the mitotic phenotypes of BAP1-deficient cells in which BRCA1 expression is restored, as well as testing whether tumour cells undergoing mitotic progression are especially sensitive to loss of BAP1. The gene discussed is BRCA1; the disease is neoplasm.